Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study

Vaccination is an effective strategy to reduce the burden of the coronavirus disease 2019 (COVID-19) pandemic. A number of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved and proven highly effective, without a counterbalancing safety signal in randomized trials [1 –4].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research

Related Links:

Abdellatif The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is currently developing into a rapidly disseminating and an overwhelming worldwide pandemic. In severe COVID-19 cases, hypercoagulability and inflammation are two crucial complications responsible for poor prognosis and mortality. In addition, coagulation system activation and inflammation overlap and produce life-threatening complications, including coagulopathy and cytokine storm, which are associated with overproduction of cytokines and activation of the immune system; they might be a lead cause of organ damage. ...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
Malay Sarkar, Irappa V Madabhavi, Pham Nguyen Quy, Manjunath B GovindagoudarAnnals of Thoracic Medicine 2022 17(1):1-13 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus responsible for the pandemic coronavirus disease 19 (COVID-19). It has significant impact on human health and public safety along with negative social and economic consequences. Vaccination against SARS-CoV-2 is likely the most effective approach to sustainably control the global COVID-19 pandemic. Vaccination is highly effective in reducing the risk of severe COVID-19 disease. Mass-scale vac...
Source: Annals of Thoracic Medicine - Category: Respiratory Medicine Authors: Source Type: research
Since the first cases were discovered at the end of 2019, the ongoing coronavirus disease 2019 (COVID-19) pandemic has significantly changed the lives of people around the world. Vaccines to prevent infection from its causative organism, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were developed by the end of 2020 and have now become humanity's hope of regaining normalcy by acquiring protective immunity against COVID-19. However, as vaccines against COVID-19 have been distributed globally at an unprecedented rate, cases of serious adverse events post-vaccination have been accumulating.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
NEW BRUNSWICK, N.J., December 16, 2021 – Johnson &Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson &Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [vi]...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Semin Thromb Hemost DOI: 10.1055/s-0041-1736168Despite the huge efforts globally underway for preventing or limiting the spread of severe acute respiratory coronavirus disease 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic outbreak appears still virtually unstoppable. As for many other infectious diseases, COVID-19 vaccination has now become crucial for limiting viral spread, especially for averting hospitalizations, need for intensive care, and fatal outcome. Nonetheless, as for other vaccines, COVID-19 vaccination is not completely free from side effects. Among the adverse events that have been reported...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Int Rev Immunol. 2021 Jul 12:1-10. doi: 10.1080/08830185.2021.1939696. Online ahead of print.ABSTRACTVaccines for the prevention of coronavirus disease 2019 (COVID-19) started to be developed since the initiation of the COVID-19 pandemic. Up to now, four vaccines have been authorized by international agencies such as European Medicines Agency (EMA). Two are DNA vaccines (ChAdOx1 nCov-19 and Ad26.COV2.S) and two mRNA vaccines (BNT162b2 and mRNA-1273). The administration of the vaccines has been associated with a strong decrease in the infections by SARS-CoV-2 and deaths associated with it. However, in parallel to these resu...
Source: International Reviews of Immunology - Category: Allergy & Immunology Authors: Source Type: research
In this report, the laboratory test processes, as utilised to assess suspected VITT, are reviewed. In published reports to date, there are notable similarities and divergences in testing approaches, potentially leading to identification of slightly disparate patient cohorts. The key to appropriate identification/exclusion of VITT, and potential differentiation from heparin-induced thrombocytopenia with thrombosis (HITT), is identification of potentially differential test patterns. In summary, testing typically comprises platelet counts, D-dimer, fibrinogen, and various immunological and functional assays for platelet facto...
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Source Type: research
Med Sci Monit. 2021 Apr 26;27:e932899. doi: 10.12659/MSM.932899.ABSTRACTDuring 2020 and 2021, the global pandemic of coronavirus disease 2019 (COVID-19) due to severe acute respi- ratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in high death rates and acute and chronic morbidity in all countries. The rapid development of new mRNA vaccines to SARS-CoV-2 brings hope that the spread of this virus can be controlled. The ChAdOx1 nCoV-19 vaccine developed by a collaboration between the University of Oxford and AstraZeneca showed efficacy in clinical trials, with a good safety profile. However, there have been recent repo...
Source: Medical Science Monitor - Category: Research Authors: Source Type: research
NEW BRUNSWICK, N.J., April 23, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company’s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combina...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: Coronavirus | COVID-19 | Hematology | Pandemics | Respiratory Medicine | SARS | Study | Thrombocytopenia | Thrombosis | Vaccines